Obtaining informed consent from vulnerable patients participating in clinical trials of investigational therapies for COVID-19 is a major ethical challenge Ethical and operational considerations - voluntariness, waiver, timing, time, documentation, and responsibilities of the sponsor, the investigator, and the ethics committee - are discussed briefly
Consent concerns in clinical trials of investigational therapies for COVID-19: Vulnerability versus voluntariness